Latest PD-L1 Lung Cancer Data Increases Debate On Biomarker
Data and filing announcements for Bristol and Merck’s PD-1 inhibitors in lung cancer put PD-L1 inhibitor developers in hot seat and create more debate about strategy and practicality of the PD-L1 biomarker.
You may also be interested in...
Studies presented at AACR highlight pros and cons of two new potential, competing frontline regimens in melanoma – Keytruda alone instead of Yervoy, or Yervoy in combination with Opdivo.
Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.